Cargando…
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma
Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating condition, with few reported cases in literature. Daratumumab is a CD38 targeted monoclonal antibody that has been widely used for the management of MM. In the absence of central nervous system (CNS) disease, many me...
Autores principales: | Kareem, Syeda Saba, Viswanathan, Neena, Sahebjam, Solmaz, Tran, Nam D, Gatewood, Tyra, Tobon, Katherine, Baz, Rachid, Piña, Yolanda, Shain, Kenneth H, Mokhtari, Sepideh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464026/ https://www.ncbi.nlm.nih.gov/pubmed/36097632 http://dx.doi.org/10.2147/OTT.S365657 |
Ejemplares similares
-
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
por: Liu, Shanshan, et al.
Publicado: (2023) -
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021) -
Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020) -
Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)